BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024 Read more about BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union Read more about Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer Read more about BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) Read more about Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem Read more about BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas Read more about BioNTech to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024 Read more about BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 Read more about BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
